Showing 3501-3510 of 5910 results for "".
- Five Coronavirus Treatments In Developmenthttps://modernod.com/news/five-coronavirus-treatments-in-development/2479524/Right now, there is only one drug shown by rigorous scientific testing to be helpful for treating COVID-19. That drug is the antiviral medication called remdesivir, made by Gilead Sciences. But remdesivir’s proven benefits
- Oxford Biomedica Snags Manufacturing Equipment to Ramp Up Production of COVID-19 Vaccinehttps://modernod.com/news/oxford-biomedica-snags-manufacturing-equipment-to-ramp-up-production-of-covid-19-vaccine/2477880/In the race for a COVID-19 vaccine, the University of Oxford has stormed to an early lead with the commercial manufacturing support of British drugmaker AstraZeneca. Now, in an effort to scale up capacity for global demand, one of AstraZeneca’s manufacturing partners has struck a deal for n
- Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With GAhttps://modernod.com/news/lineage-cell-therapeutics-reports-regeneration-of-retinal-tissue-in-patient-treated-with-opregen-rpe-cells-for-dry-amd-with-ga/2477845/Lineage Cell Therapeutics announced that restoration of retinal tissue was observed in a patient enrolled in a phase 1/2a study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of dry age-related macular degenerati
- Gene Therapy Program at Penn Medicine Joins AAVCOVID Vaccine Projecthttps://modernod.com/news/gene-therapy-program-at-penn-medicine-joins-aavcovid-vaccine-project/2477832/The Gene Therapy Program at the University of Pennsylvania is joining the AAVCOVID vaccine program led by Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham for the joint research program. AAVCOVID is a unique gene-based vaccine candidate designed
- Nearly Half Of Americans Delayed Medical Care Due To Pandemichttps://modernod.com/news/nearly-half-of-americans-delayed-medical-care-due-to-pandemic/2477828/As the coronavirus threat ramped up in March, hospitals, health systems and private practices dramatically reduced inpatient, nonemergency services to prepare for an influx of COVID-19 patients, according to a Kaiser Health News
- Reopen Eyecare Website Launches Todayhttps://modernod.com/news/reopen-eyecare-website-launches-today/2477805/Reopeneyecare.com, a new digital platform designed to help eyecare providers navigate the implications of the COVID-19 pandemic on their businesses, launched today. Featuring content specially curated by a taskforce of vision community leaders and sponsored by The Vision Council, the website is i
- Gilead Inks Non-US Deals With Five Generic Drugmakers to Expand Supply of COVID-19 Drug Remdesivirhttps://modernod.com/news/gilead-inks-non-us-deals-with-five-generic-drugmakers-to-expand-supply-of-covid-19-drug-remdesivir/2477757/Gilead Sciences said it has signed non-exclusive voluntary licensing agreements with Cipla, Ferozsons Laboratories, Hetero Labs, Jubilant Lifesciences and Mylan to manufacture COVID-19 treatment remdesivir for distribution in 127 countries. According to Gilead, the list consists of nearly all low
- FDA Approves Quidel’s Sofia 2, First Antigen Test to Help in the Rapid Detection of COVID-19https://modernod.com/news/quidel-receives-emergency-authorization-for-rapid-antigen-covid-19-diagnostic-assay/2477735/Quidel, which makes diagnostic tests for a variety of conditions including acute conjunctivitis and dry eye disease, announced that it has received Emergency Use Authorization (EUA) from the FDA to market its Sofia 2
- Insight Into FDA’s Revised Policy on Antibody Tests: Prioritizing Access and Accuracyhttps://modernod.com/news/insight-into-fdas-revised-policy-on-antibody-tests-prioritizing-access-and-accuracy/2477725/In a blog post on the FDA website, agency leaders outlined a new policy that aims to provide more oversight of COVID-19 antibody tests. The revised policy on antibody tests was written by Anand Shah, MD, Deputy Commissioner for Medical and Scientific Affairs, and Jeff Shuren, MD, Director,
- Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophyhttps://modernod.com/news/lineage-cell-therapeutics-reports-new-data-with-opregen-for-the-treatment-of-dry-amd-with-geographic-atrophy/2477713/Lineage Cell Therapeutics announced that updated results from a phase 1/2a study of its lead product candidate OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), were published online via th